Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes

作     者：Cheng-Rui Li Bas J.G.Baaten Linda M.Bradley 

作者机构：Infectious and Inflammatory Disease CenterSanford-Burnham Medical Research Institute10901 North Torrey Pines RoadLa JollaCA 92037USA 

出 版 物：《分子细胞生物学报:英文版》 (Journal of Molecular Cell Biology)

年 卷 期：2012年第4卷第1期

页      面：38-47页

核心收录：

学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the National Institutes of Health (NIH,AI081238) Juvenile Diabetes Research Foundation (JDRF,31-2008-353) 

主　　题：type 1 diabetes adaptive regulatory T cells autoimmunity immunotherapy 

摘      要：Type 1 diabetes(T1D)results from autoimmune destruction of insulin-producing b-cells in the pancreatic *** is an immediate need to restore both b-cell function and immune tolerance to control disease progression and ultimately cure ***,there is no effective treatment strategy to restore glucose regulation in patients with ***3-expressing CD4^(+) regulatory T cells(Tregs)are potential candidates to control autoimmunity because they play a central role in maintaining ***,deficiencies in either naturally occurring Tregs(nTregs)themselves and/or their ability to control pathogenic effector T cells have been associated with ***,we hypothesize that nTregs can be replaced by FoxP3^(+) adaptive Tregs(aTregs),which are uniquely equipped to combat autoreactivity in *** nTregs,aTregs are stable and provide long-lived *** this review,we summarize the current understanding of aTregs and their potential for use as an immunological intervention to treat T1D.